Piper Jaffray analyst Christopher Raymond reiterated an Overweight rating and $60.00 price ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Aimmune Therapeutics (AIMT) Gains a Briefing Docs Seen as 'Fairly Benign'September 11, 2019 9:35 AM Pre-Open 09/11: (TTOO) (LXRX) (LOVE) Higher (ZS) (GME) (PLAY) Lower (more...)September 11, 2019 9:16 AM FDA Posts Briefing Document for Aimmune Therapeutics' (AIMT) PalforziaSeptember 11, 2019 8:05 AM Aimmune Therapeutics (AIMT) Added to Fresh Pick List at BairdSeptember 9, 2019 7:36 AM